Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, doub...

by Adam J. Savitz, Haiyan Xu, Srihari Gopal, Isaac Nuamah, Maju Mathews, Bernardo Soares
Published 2019-04-01

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies

by Srihari Gopal, Haiyan Xu, Kelly McQuarrie, Adam Savitz, Isaac Nuamah, Kimberly Woodruff, Maju Mathews
Published 2017-07-01

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate

by Rebekka Lencer, Maria Paz Garcia-Portilla, Paul Bergmans, Srihari Gopal, Maju Mathews, Annette Wooller, Katalin Pungor
Published 2021-05-01

Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

by Katalin Pungor, Vasilis P. Bozikas, Robin Emsley, Pierre-Michel Llorca, Srihari Gopal, Maju Mathews, Annette Wooller, Paul Bergmans
Published 2020-12-01